[KLK] YoY Annualized Quarter Result on 30-Jun-2018 [#3]

Announcement Date
14-Aug-2018
Admission Sponsor
-
Sponsor
-
Financial Year
30-Sep-2018
Quarter
30-Jun-2018 [#3]
Profit Trend
QoQ- -14.78%
YoY- -14.57%
View:
Show?
Annualized Quarter Result
30/06/21 30/06/20 30/06/19 30/06/18 30/06/17 30/06/16 30/06/15 CAGR
Revenue 18,641,684 15,456,730 15,641,978 18,946,032 21,120,338 15,950,465 12,957,210 6.24%
PBT 2,795,294 1,132,586 769,586 1,262,920 1,425,870 1,957,754 1,202,784 15.07%
Tax -453,416 -308,904 -161,766 -328,888 -357,834 -249,313 -257,784 9.85%
NP 2,341,878 823,682 607,820 934,032 1,068,036 1,708,441 945,000 16.31%
-
NP to SH 2,175,712 751,717 589,981 869,104 1,017,341 1,622,845 911,498 15.58%
-
Tax Rate 16.22% 27.27% 21.02% 26.04% 25.10% 12.73% 21.43% -
Total Cost 16,299,805 14,633,048 15,034,158 18,012,000 20,052,302 14,242,024 12,012,210 5.21%
-
Net Worth 12,047,315 10,752,433 10,489,912 11,235,388 11,341,884 9,808,334 8,775,317 5.41%
Dividend
30/06/21 30/06/20 30/06/19 30/06/18 30/06/17 30/06/16 30/06/15 CAGR
Div 287,611 215,695 212,993 212,993 212,993 212,993 212,993 5.12%
Div Payout % 13.22% 28.69% 36.10% 24.51% 20.94% 13.12% 23.37% -
Equity
30/06/21 30/06/20 30/06/19 30/06/18 30/06/17 30/06/16 30/06/15 CAGR
Net Worth 12,047,315 10,752,433 10,489,912 11,235,388 11,341,884 9,808,334 8,775,317 5.41%
NOSH 1,081,017 1,081,017 1,064,965 1,064,965 1,064,965 1,064,965 1,064,965 0.24%
Ratio Analysis
30/06/21 30/06/20 30/06/19 30/06/18 30/06/17 30/06/16 30/06/15 CAGR
NP Margin 12.56% 5.33% 3.89% 4.93% 5.06% 10.71% 7.29% -
ROE 18.06% 6.99% 5.62% 7.74% 8.97% 16.55% 10.39% -
Per Share
30/06/21 30/06/20 30/06/19 30/06/18 30/06/17 30/06/16 30/06/15 CAGR
RPS 1,728.42 1,433.20 1,468.78 1,779.03 1,983.19 1,497.74 1,216.68 6.02%
EPS 201.73 70.13 55.33 81.60 95.47 152.40 85.60 15.34%
DPS 26.67 20.00 20.00 20.00 20.00 20.00 20.00 4.90%
NAPS 11.17 9.97 9.85 10.55 10.65 9.21 8.24 5.19%
Adjusted Per Share Value based on latest NOSH - 1,064,965
30/06/21 30/06/20 30/06/19 30/06/18 30/06/17 30/06/16 30/06/15 CAGR
RPS 1,653.12 1,370.68 1,387.11 1,680.11 1,872.92 1,414.47 1,149.03 6.24%
EPS 192.94 66.66 52.32 77.07 90.22 143.91 80.83 15.58%
DPS 25.50 19.13 18.89 18.89 18.89 18.89 18.89 5.12%
NAPS 10.6834 9.5351 9.3023 9.9634 10.0578 8.6979 7.7818 5.41%
Price Multiplier on Financial Quarter End Date
30/06/21 30/06/20 30/06/19 30/06/18 30/06/17 30/06/16 30/06/15 CAGR
Date 30/06/21 30/06/20 28/06/19 29/06/18 30/06/17 30/06/16 30/06/15 -
Price 20.36 22.20 24.56 24.16 24.88 23.26 21.40 -
P/RPS 1.18 1.55 1.67 1.36 1.25 1.55 1.76 -6.44%
P/EPS 10.09 31.85 44.33 29.60 26.04 15.26 25.00 -14.02%
EY 9.91 3.14 2.26 3.38 3.84 6.55 4.00 16.30%
DY 1.31 0.90 0.81 0.83 0.80 0.86 0.93 5.87%
P/NAPS 1.82 2.23 2.49 2.29 2.34 2.53 2.60 -5.76%
Price Multiplier on Announcement Date
30/06/21 30/06/20 30/06/19 30/06/18 30/06/17 30/06/16 30/06/15 CAGR
Date 18/08/21 19/08/20 20/08/19 14/08/18 15/08/17 17/08/16 19/08/15 -
Price 19.88 22.60 23.82 24.86 24.68 23.22 20.22 -
P/RPS 1.15 1.58 1.62 1.40 1.24 1.55 1.66 -5.92%
P/EPS 9.85 32.42 43.00 30.46 25.84 15.24 23.62 -13.55%
EY 10.15 3.08 2.33 3.28 3.87 6.56 4.23 15.69%
DY 1.34 0.88 0.84 0.80 0.81 0.86 0.99 5.16%
P/NAPS 1.78 2.27 2.42 2.36 2.32 2.52 2.45 -5.18%

PBT = Profit before Tax, NP = Net Profit, NP to SH = Net Profit Attributable to Shareholder, Div = Dividend, NP Margin = Net Profit Margin, ROE = Return on Equity, NOSH = Number of Shares, RPS = Revenue per Share, EPS = Earning Per Share, DPS = Dividend Per Share, NAPS = Net Asset Per Share, EOQ = End of Quarter, ANN = Announcement, P/RPS = Price/Revenue per Share, P/EPS = Price/Earning per Share, P/NAPS = Price/Net Asset per Share, EY = Earning Yield, DY = Dividend Yield.

NOSH is estimated based on the NP to SH and EPS. Div is an estimated figure based on the DPS and NOSH. Net Worth is an estimated figure based on the NAPS and NOSH.

Div Payout %, NP Margin, ROE, DY, QoQ & YoY figures in Percentage; RPS, EPS & DPS's figures in Cent; and NAPS's figures in Dollar.

All figures in '000 unless specified.

Discussions
Be the first to like this. Showing 0 of 0 comments

Post a Comment